P-(GFLG)-DOX-GalN (25,000 g/mol; Fig. 4B), contains N-acylated galactosamine (GalN), which was designed to be recognized by ASGPR in HepG2 human hepatocellular carcinoma cells (59,82) and individual members of the galectin family (e.g., galectin-3) in human colon adenocarcinoma (83,84). Here, LGALS3 is linked to colon adenocarcinoma.